Micafungin
- Generic Name
- Micafungin
- Brand Names
- Mycamine
- Drug Type
- Small Molecule
- Chemical Formula
- C56H71N9O23S
- CAS Number
- 235114-32-6
- Unique Ingredient Identifier
- R10H71BSWG
- Background
Micafungin is an antifungal drug. It belongs to the antifungal class of compounds known as echinocandins and exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall.
- Indication
Indicated for the treatment of candidemia, acute disseminated candidiasis, and certain other invasive Candida infections, as well as esophageal candidiasis, and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation. Micafungin is also used as an alternative for the treatment of oropharyngeal candidiases and has been used with some success as primary or salvage therapy, alone or in combination with other antifungals, for the treatment of invasive aspergillosis.
Indicated for the prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation.
- Associated Conditions
- Abscesses, Aspergillosis, Candidemia, Candidiasis, Esophageal Candidiasis, Fungal Infections, Fungal peritonitis caused by Candida, Acute disseminated Candidiasis
Micafungin Versus AmBisome in Invasive Candidiasis and Candidemia
- First Posted Date
- 2005-03-23
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 637
- Registration Number
- NCT00106288
Study of Micafungin in Patients With Invasive Candidiasis or Candidemia
- First Posted Date
- 2005-03-08
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 611
- Registration Number
- NCT00105144
Phase I Study of the Safety, Tolerance, and Pharmacokinetics of FK463 in Immunocompromised Children With Fever and Neutropenia
- Conditions
- FeverMycosesNeutropenia
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 120
- Registration Number
- NCT00001790
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Comparing the Effectiveness of Fluconazole and a New Medicine (FK463) in Preventing Fungal Infections in Bone Marrow Transplant Patients
- Conditions
- AspergillosisCandidiasisFungemiaMycoses
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 800
- Registration Number
- NCT00001937
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Comparative Study of Micafungin (FK463) Versus Placebo as Prophylactic Antifungal Therapy in the ICU
- First Posted Date
- 2002-11-08
- Last Posted Date
- 2012-03-27
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 104
- Registration Number
- NCT00048750
Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for Aspergillosis
- First Posted Date
- 2002-10-24
- Last Posted Date
- 2014-08-20
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 2
- Registration Number
- NCT00047827
Study of FK463 for the Treatment of Invasive Aspergillosis
- Conditions
- Aspergillosis
- First Posted Date
- 2002-05-09
- Last Posted Date
- 2018-01-10
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 326
- Registration Number
- NCT00036166
- Locations
- 🇫🇷
Hopital Henri Mondor, Service d'Hematologie Clinique, Creteil, France
🇫🇷Hotel Dieu, Service d'Hematologie, Nantes, France
🇫🇷Hopital Saint Louis, Service D'Hematologie/Greffe de Moelle, Paris, France
Study of FK463 in the Treatment of Candidemia or Invasive Candidiasis
- Conditions
- Candidiasis
- First Posted Date
- 2002-05-09
- Last Posted Date
- 2018-01-10
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 75
- Registration Number
- NCT00036179
- Locations
- 🇫🇷
Hopital Henri Mondor, Dervice d'Hematologie Clinique, Creteil, France
🇩🇪Klinikum der Stadt, Medizinische Klinik A, Ludwigshafen, Germany
🇩🇪Universitat Wurzburg, Institut fur Molekulare und Infectionsbiologie, Wurzburg, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.